Open AccessAssociation between human glutathione S-transferase omega rs4925 polymorphism and bladder cancer
Author(s) -
Su-Wei Hu,
YenHao Su,
Zhon-Min Huang,
HsinAn Chen,
Wei Yu Kao,
Yuan–Hung Wang,
ChiaChang Wu
Publication year - 2013
Publication title -
advances in bioscience and biotechnology
Language(s) - English
Resource type - Journals
eISSN - 2156-8502
pISSN - 2156-8456
DOI - 10.4236/abb.2013.41009
Subject(s) - genotype , odds ratio , genotyping , glutathione , bladder cancer , glutathione s transferase , confidence interval , single nucleotide polymorphism , genetics , biology , gene , medicine , gastroenterology , microbiology and biotechnology , oncology , cancer , enzyme , biochemistry
Glutathione S-transferases (GSTs) play an important role in the detoxification of polycyclic aromatic hydrocarbons and aromatic amines, the toxic substances contained in cigarettes. GST Omega 1 (GSTO1) not only utilizes glutathione in conjugation reaction but also contributes to the biotransformation of several xenobiotics. A single nucleotide polymorphism (Ala-140Asp) of GSTO1 gene causing variations in enzyme activity may influence individual susceptibility to bladder cancer (BC). It is hypothesized that genetic polymorphism of GSTO1 gene has an effect on BC risk in particular by interacting with cigarette smoking. A total of histopathologically confirmed 300 BC patients and 300 cancer-free controls were recruited from February 2002 to February 2009. Genotyping of the GSTO1 Ala140Asp polymorphism was determined using a polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP) method. The odds ratio (OR) and 95% confidence interval (CI) were calculated as a measure of the combined effect of cigarette smoking and the GSTO1 Ala140Asp polymorphism on BC risk. We found that study subjects with the GSTO1 Ala/Ala genotype have a significantly increased BC risk (OR = 1.5; 95% CI = 1.1 - 2.7). A statistically significant increased BC risk was also found in ever smokers with the GSTO1 Ala/Ala genotype (OR = 4.9; 95%CI = 2.8 - 9.7). In conclusion, this study provides an epidemiologic evidence of a significantly increased BC risk among ever smokers with the GSTO1 Ala/Ala genotype.